Description

Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)—-C68H115N19O22S2—-[1]Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.|[2]Jun Yang, et al. Upregulation of microRNA-590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor-β1/phosphoinositide 3-kinase/Akt signaling. Int J Mol Med. 2019 May;43(5):2212-2220.|[3]Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654.|[4]Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an “In Vivo” Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10(12):e0144489.|[5]Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381(1):67-75.—-1614.88–99.53–O=C([C@@H](N)[C@@H](C)O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C([O-])=O)CC(N)=O)=O)CCC(N)=O)=O)CCSC)=O)CCSC)=O)C)=O)CC1=CNC2=CC=CC=C12)=O)[C@H](CC)C)=O)[C@H](CC)C)=O)CO)=O)C)=O)CC([O-])=O)=O)CC(C)C)=O)CO.[NH4+].[NH4+]–Cancer–DMSO : 10 mg/mL (ultrasonic)|H2O : 9.09 mg/mL (ultrasonic;adjust pH to 9 with NH3·H2O)–Apoptosis;PI3K;TGF-beta/Smad—-Apoptosis;PI3K/Akt/mTOR;Stem Cell/Wnt;TGF-beta/Smad–Peptides